BPC-157: the human data we have

How much research is there on BPC-157?

BPC-157 has more than three decades of animal research behind it and only a handful of people in its published human studies. PubMed holds 235 records on it, the first from the early 1990s⁶. The people in its published human studies add up to 30¹²³.

The gap comes from who did the work. About three in four of those records carry the name of Predrag Sikiric, whose group at the University of Zagreb discovered the peptide, and that group has spent three decades testing it in rats: cut tendons, cut ligaments, stitched bowels¹¹¹³¹⁴. Labs in Taiwan and China have since confirmed key pieces of how it works and how the body clears it⁸⁹¹⁵. What it has never had is a drug company carrying it through large human trials to approval.

Which human studies have been published?

Three, all pilots. Here is each one, how big it was and what it found.

All three come from one physician, Edwin Lee, working in private clinics, and all three appeared in the journal Alternative Therapies in Health and Medicine. None had a comparison group. The knee study was a chart review: patients rated their own pain by phone, most of them six months to a year after the injection, and a 2025 systematic review notes that 7 of the 12 reported relief lasting more than six months⁵. A 2025 review from the University of Utah counts the same three pilots as the whole published human record, with no adverse effects reported in any of them⁴.

The doses in the table are what each study used. They describe the research, not a protocol to copy.

What did the bladder study find?

It is the most striking of the three. Interstitial cystitis, also called bladder pain syndrome, is a painful long-term condition with few treatments that work well. All 12 women in the study had already tried pentosan polysulfate, the approved drug, without a response².

Each had a single procedure in which BPC-157 was injected around the inflamed area of the bladder. Afterwards, 10 of the 12 reported that their symptoms had resolved completely, and the other 2 rated their improvement at 80%. No one dropped out, and no adverse events were recorded². Twelve people and no control group is a small base, but it is the kind of result that earns a proper trial.

Are there controlled trials underway?

One, and it is the first of its kind in patients. The University of Arkansas has registered a randomized, quadruple-blinded trial of BPC-157 after rotator cuff repair surgery: a planned 30 patients, daily injections under the skin for 90 days after the operation, and tendon healing checked by MRI alongside strength, range of motion and patient-reported scores. It is not yet recruiting, with an estimated start of January 2027¹⁶.

Two other records exist on ClinicalTrials.gov. A placebo-controlled phase 1 trial of BPC-157 tablets in 42 healthy volunteers in Mexico was registered in 2015 and never updated, and it has posted no results¹⁷. A study of BPC-157 gummies in 40 active adults, with no comparison group, finished in November 2025 and has not posted results either¹⁸.

Earlier still, its developers report that BPC-157 reached phase II trials for inflammatory bowel disease under the code PL 14736, with no side effects in those trials⁷¹⁴. Full results from them have not been published in PubMed.

How does BPC-157 work?

BPC-157 is a chain of 15 amino acids, GEPPPGKPADDAGLV, cut from a larger protein its discoverers isolated from human gastric juice⁶⁹. That origin explains one of its unusual traits: it holds up in human gastric juice, so in rats it works by mouth as well as by injection⁷¹³.

Peptide SkySee BPC-157 as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky

No known human gene spells it. The sequence of the parent protein has not been published, and in our own search of all 20,442 reviewed human proteins in UniProt (October 2026), none contains even seven of BPC-157's 15 amino acids in a row.

Its main job in the animal work is building blood supply. In rats with a blocked leg artery, it restored blood flow faster and grew more vessels; in human blood-vessel cells in a dish, it raised VEGFR2, the receptor that drives vessel growth, and switched on the Akt–eNOS nitric-oxide pathway⁸. New vessels matter most where tissue has few of them, which is why tendons and the junctions between muscle and tendon are where it stands out⁴.

It also works on the repair cells themselves. Rat tendon cells treated with BPC-157 grew out of pieces of tendon faster, moved further and survived stress better⁹. They also carried more growth hormone receptors, so added growth hormone made them multiply faster¹⁰.

In whole rats, the results line up. Cut Achilles tendons healed stronger, with better function by day 14¹¹. Tendons cut from the heel bone reattached better over 21 days, with better-organized collagen¹². Cut knee ligaments healed better throughout 90 days, whether the peptide was injected, put in drinking water or applied as a cream¹³. A stitched bowel held more pressure before leaking¹⁴. Across 35 animal and lab studies, a 2025 systematic review found better function, structure and strength in injured muscle, tendon, ligament and bone⁵.

It is also fast. In rats and dogs, its half-life was under 30 minutes, and the body broke it down into ordinary amino acids¹⁵. Its half-life in people is not yet established.

What do people who use it report?

Commonly reported: tendon and ligament pain easing within the first one to three weeks, a calmer gut with less reflux or bloating (especially when taken by mouth), and mild injection-site irritation that passes on its own.

These are user reports, not trial results. The two treatment pilots point the same way: in both, most patients reported relief after a single treatment¹²⁵. Healing is gradual, so the first weeks are a good time to note how an injury moves and hurts, as a baseline for later.

Is BPC-157 approved or allowed in sport?

It is not an FDA-approved drug⁵. The World Anti-Doping Agency names it on its 2026 Prohibited List under non-approved substances, banned in and out of competition, so it is off limits for tested athletes¹⁹. The FDA lists BPC-157 among substances nominated for pharmacy compounding and later withdrawn, noting a possible risk of immune reactions by some routes and little safety information to go on²⁰. Reviewers flag unregulated manufacturing and possible contamination as the practical concerns⁵.

What would settle the question?

A randomized, blinded trial with imaging, which is exactly what the Arkansas rotator cuff study is built to be¹⁶. Until it reports, the picture is clear enough to state plainly: a deep and consistent animal record on tendon, ligament and gut repair, three encouraging human pilots, and the first real test of it in people on the calendar.